Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Authors :: Johan Vansteenkiste
Juergen Wolf
P.J. Souquet
Noemí Reguart
T. Hida
Takashi Seto
Harry J.M. Groen
M.J.A. de Jonge
J-Y. Han
Rebecca S. Heist
Egbert F. Smit
M. Waldron-Lynch
D.S.W. Tan
Anna Robeva
Sergey Orlov
S. Le Mouhaer
Monica Giovannini
Edward B. Garon
Source :: Annals of Oncology. 29:viii741-viii742
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Oncology
Brachial Plexus Neuritis
medicine.medical_specialty
Capmatinib
business.industry
non-small cell lung cancer (NSCLC)
Phases of clinical research
Hematology
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Mutation (genetic algorithm)
Medicine
In patient
business

Full Text Access

Tools